Perspectives in Urology Point Counterpoint 2018

Genetic Testing and Next Generation DNA Sequencing

Alan H. Bryce, MD, explains the concept of synthetic lethality in the context of BRCA-deficient tumors, as well as resistance to poly (ADP-ribose) polymerase (PARP) inhibition. He also discusses the under-utilization of inherited cancer risk syndromes in prostate cancer practice, research, and guidelines, as well as new pathways for therapeutic targeting

Read More

Treating BPH- Comparing HoLEP, Rezum, and Urolift

Scott M. Cheney, MD, reviews the background and practical application of minimally-invasive surgical therapies and definitive therapies for benign prostatic hyperplasia (BPH). He then discusses patient selection for these therapy options based on recommendations, level of evidence, and comparative outcomes.

Read More
Loading

Join the GRU Community

- Why Join? -